NeuroField is a multimodal brain measurement, neurostimulation, and reporting ecosystem used by clinicians, researchers, and academic institutions to capture, analyze, and modulate brain activity. The questions below are designed to help practitioners, research teams, and our at-home users quickly understand our technology, our product line, and how NeuroField fits into clinical and investigational workflows, and the neurotechnology field.
NeuroField is a neurotechnology hardware and software ecosystem built around three core capabilities: brain measurement (EEG, QEEG, ERP), advanced neuroanalysis, and multimodal neurostimulation. Designed and developed by clinicians for clinicians, NeuroField turns raw brain data into quantified, clinically actionable reports and supports a wide range of neuromodulation modalities for clinics, research, and personal use.
NeuroField builds three product tiers: clinical systems for practitioners conducting QEEG and ERP assessments and neurotherapy, research-only systems for academic and investigational use, and personal-use devices for at-home applications such as Genesis for chronic insomnia.
NeuroField is headquartered at 1836 State St, Santa Barbara, CA 93101. The company is led by neuroscientists, engineers, and practicing clinicians with over three decades of experience in neuroscience and applied neuromodulation, including co-founders Dr. Nicholas Dogris and Brad Wiitala, and Dr. Sahin Ozsoy.
Most neurofeedback or neurostimulation systems do one thing well. NeuroField was built around the practitioner workflow: a high-fidelity 19-channel EEG amplifier (Q21), a fully integrated impedance meter (Q-Check), an FDA-cleared analysis suite for EEG and ERP, and a single multimodal stimulator (Genesis + optional RUO NF64) capable of delivering tDCS, tACS, tRNS, pink and brown noise, and tVNS within one device. Combined with the RUO Neurofeedback software module and the RUO AI Profiler and Protocol Generator, this allows practitioners and researchers to move from acquisition to analysis to neurofeedback training to protocol selection inside a single ecosystem.
Neurotechnology is the umbrella term for hardware and software designed to measure, interpret, or modulate activity in the central nervous system. It includes brain-measurement tools (EEG, QEEG, ERP), neuromodulation devices (4 forms of transcranial electrical stimulation, pulsed electromagnetic field, photobiomodulation, transcranial vagus nerve stimulation), neurofeedback systems, and the analytical software that links them together. NeuroField develops integrated neurotechnology that connects measurement and modulation in a single ecosystem, giving practitioners and researchers a complete workflow rather than disconnected tools.
Electroencephalography, or EEG, is the measurement of electrical activity at the surface of the scalp. EEG primarily reflects activity from the cortex (the outer layer of the brain) and produces continuous waveforms that clinicians and researchers analyze to understand brain function. EEG is non-invasive and is recorded using small electrodes placed on the scalp.
Quantitative EEG, also called brain mapping, is the digital quantification and statistical analysis of EEG data. After a 19- or 20-channel raw EEG is recorded, the data is processed against normative databases of healthy individuals matched for age, as well as independently from databases to show the client’s unique findings. The output is a stand-alone and comparative profile of the patient’s brainwave activity expressed as head maps, spectra, indices, independent components, and numerical tables. QEEG is a foundational assessment tool in neurotherapy, neuropsychology, and applied neuroscience.
Event-related potentials are time-locked EEG responses elicited by a specific sensory, cognitive, or motor stimulus. ERPs allow clinicians and researchers to evaluate the brain’s processing of attention, memory, decision-making, and inhibition. NeuroField’s ERP module supports continuous ERP tasks using visual, auditory, or combined stimuli, and includes programmable Oddball and GO/NOGO Matching paradigms with quantified output.
Neurofeedback is a form of operant conditioning in which the brain is rewarded in real time when it produces target patterns of activity. The patient receives visual or auditory feedback contingent on their EEG, and over repeated sessions the brain learns to self-regulate. The NeuroField Neurofeedback module (research use only) supports amplitude, ratio, connectivity, phase, slow cortical potential, and phase–amplitude coupling protocols across all major frequency bands from Delta through Gamma, with both surface and sub-cortical training environments.
Neurostimulation, also called neuromodulation, applies low-level electrical, electromagnetic, or photonic energy to influence brain activity directly. Neurofeedback, in contrast, is an indirect approach: the patient is shown real-time information about their own brainwaves and is conditioned to produce desired patterns over time. Both have a place in clinical practice, but they are not equivalent in mechanism, depth, or speed.
Neurostimulation is generally the more advanced and clinically efficient approach for several reasons. It acts directly on neural tissue rather than depending on the patient’s ability to learn, attend, or sit still long enough to be conditioned. It can target deeper cortical and sub-cortical regions through anatomically guided electrode placement, including the 68 regions of the Desikan–Killiany Brain Atlas supported by NeuroField’s Stimulation Targeting Tool. It can layer multiple modalities — tDCS, tACS, tRNS, pink and brown noise, pEMF, photobiomodulation, and tVNS — within a single session, and it generally produces measurable change in fewer sessions than neurofeedback alone.
Neurofeedback retains an important place in the field. It builds durable self-regulation skills, gives patients a sense of agency over their own physiology, and can be highly effective for attention training, peak performance, and certain anxiety presentations. In clinical practice, the two modalities are most powerful when combined: neurostimulation to shift the underlying state, neurofeedback to consolidate and reinforce the change. The RUO NeuroField Neurofeedback module supports this combined workflow within the same software environment used for acquisition and analysis.
Neurotherapy is the clinical integration of EEG-based assessment, neurofeedback, and neurostimulation. The term was originally used by EEG neurodiagnostician Juri Kropotov to describe the combined application of feedback and stimulation technologies. In practice, neurotherapy refers to the data-driven use of brain measurement to guide individualized neuromodulation protocols.
EEG activity is conventionally divided into bands by frequency in hertz. Each band is associated with different brain states and clinical signatures, and most NeuroField protocols are designed to target activity in specific bands.
| Band | Range (Hz) | Commonly associated with |
|---|---|---|
| Delta | 0–4 Hz | Deep sleep, restorative processes, certain pathologies when present in waking states |
| Theta | 5–8 Hz | Drowsiness, daydreaming, memory consolidation, attention regulation |
| Alpha | 9–12 Hz | Relaxed wakefulness, idling cortex, eyes-closed resting state |
| Low Beta | 13–16 Hz | Calm focused attention, sensorimotor activity |
| Mid Beta | 17–25 Hz | Active thinking, problem solving, engaged cognition |
| High Beta | 26–40 Hz | Hyperarousal, anxiety, intensive cognitive load |
| Gamma | 41–70 Hz | Cross-network binding, perception, higher-order cognition |
NeuroField builds an integrated ecosystem of EEG hardware, neurostimulation hardware, and analysis software, delivered in three tiers: clinical, research-only, and personal-use. The table below summarizes each product and its primary role.
| Product | Type | Primary use |
|---|---|---|
| Q21 | 19-channel EEG amplifier (FDA 510(k) cleared) | High-fidelity EEG and QEEG acquisition for clinical, ERP, and neuromodulation workflows |
| Q-Check | 20-channel impedance meter | Quality-control before EEG acquisition; ensures electrode contact and clean signal |
| NeuroField Analysis Suite (EEG + ERP Modules) | FDA 510(k) cleared analysis software | Acquisition, brain mapping, ERP analysis, comparative reports in Microsoft Word |
| Genesis | Self-contained cranial electrical stimulator (FDA 510(k) cleared) | FDA-cleared treatment of chronic insomnia in clinical and prescription home-use settings |
| NeuroField64 (NF64) | Research Use Only (RUO) neurostimulation software add-on | Independent simultaneous control of two Genesis units; over 250 protocols across all stimulation modalities |
| Neurofeedback Software Module | RUO multimodal neurofeedback training environment | Amplitude, ratio, connectivity, phase, slow cortical potential, and phase–amplitude coupling protocols across all major frequency bands; surface and sub-cortical training |
| AI Profiler and Protocol Generator | RUO cloud-based analysis and protocol-matching engine | Pattern matching across classifiers and selection from hundreds of NeuroField research protocols |
| Stimulation Targeting Tool | RUO electrode-placement guidance tool | Maps electrode positions to the 68 cortical and sub-cortical regions of the Desikan–Killiany Brain Atlas |
| Statistical Comparison Tool | RUO comparison and outcomes analysis tool | Compares EEG, ERP, and neurofeedback data across sessions for individual or group-level outcome tracking |
Detailed specifications, kit contents, and configuration options for each product are available on the corresponding product pages.
When paired with NF64, the Genesis device can deliver six distinct neurostimulation modalities at intensities ranging from 0.01 to 2.5 mA. Each modality has a specific waveform, frequency range, and clinical or research rationale. The table below summarizes the modalities and their parameters.
| Modality | Abbreviation | Frequency / Parameters | What it does |
|---|---|---|---|
| Transcranial Direct Current Stimulation | tDCS | DC, 0.01–2.5 mA | Constant low-amplitude direct current; modulates cortical excitability anodally or cathodally |
| Transcranial Alternating Current Stimulation | tACS | 0.01–15,000 Hz (with NF64) | Sinusoidal alternating current targeted to specific frequency bands; entrainment of oscillatory activity |
| Transcranial Random Noise Stimulation | tRNS | 1–9,000 Hz | Stochastic resonance across a broad frequency range; non-selective excitability modulation |
| Transcranial Advanced Pink Noise Stimulation | tAPNS | 10–9,000 Hz | 1/f-weighted noise distribution; biologically plausible spectral profile |
| Transcranial Advanced Brown Noise Stimulation | tABNS | 0–10 Hz | 1/f² weighted low-frequency noise; concentrated in slow rhythm bands |
| Transcranial Vagus Nerve Stimulation | tVNS | 1 Hz, 100 Hz, 15 kHz biphasic | Non-invasive vagal pathway stimulation |
Pulsed electromagnetic field (pEMF) stimulation and photobiomodulation (PBM) are part of the broader NeuroField research training curriculum and are integrated into the clinical workflow alongside transcranial electrical stimulation. pEMF is a clinically applied modality used in NeuroField protocols, and PBM (low-level light therapy) is incorporated to target additional cellular and neural mechanisms. Specific deployment depends on the hardware configuration in use.
tDCS delivers a constant direct current across two electrodes; the polarity (anode vs. cathode) determines the direction of cortical excitability change. tACS delivers an oscillating current at a defined frequency, intended to entrain or modulate the brain’s endogenous rhythms. tDCS is generally used to shift overall excitability; tACS is generally used to influence specific frequency-band dynamics.
NeuroField’s Stimulation Targeting Tool (free with the research download) maps electrode positions to any of the 68 cortical and sub-cortical regions defined in the Desikan–Killiany Brain Atlas. This allows researchers to translate data-driven insight from QEEG and ERP into anatomically precise electrode placement.
NeuroField’s FDA-cleared products are cleared for specific intended uses (EEG acquisition and analysis, ERP, and treatment of chronic insomnia). Beyond those FDA-cleared indications, NeuroField’s research-only tools and AI Profiler and Protocol Generator classifiers support investigation across a wide range of conditions, including:
Outside the explicit FDA-cleared indications, all clinical and research observations are framed in terms of practitioner experience, clinical observation, and research investigation rather than RCT-level efficacy claims.
In general, NeuroField protocols can be applied while a patient is on medication, but specific decisions are made by the prescribing clinician with knowledge of the individual patient. Each medication has different potential interactions with arousal, sleep, and cortical excitability, and protocol intensity may be adjusted accordingly.
No. Neurofeedback and neurostimulation are designed to support normalization and self-regulation of brain activity; they do not alter personality. Clinicians often describe outcomes in terms of reduced symptom burden and improved regulation, not personality change.
Most patients receiving a complete course of neurotherapy report durable changes. Some return for periodic “tune-up” sessions, but this is generally not required. Persistence of underlying medical or metabolic pathology, or progressive disease, can affect how long benefits hold.
NeuroField’s clinical hardware and software products are FDA cleared, not FDA approved. These are two distinct regulatory pathways, and the difference matters. The Q21 EEG amplifier, the NeuroField Analysis Suite (EEG and ERP modules), and Genesis are all FDA 510(k) cleared. NeuroField’s research-only products (NF64, AI Profiler and Protocol Generator, Neurofeedback module, Stimulation Targeting Tool, Statistical Comparison Tool) are not FDA cleared and are designated for research use only.
Both are FDA regulatory designations, but they apply to different categories of medical device and require different evidence.
| Category | FDA Clearance (510(k)) | FDA Approval (PMA) |
|---|---|---|
| Pathway | Premarket Notification under 510(k) | Premarket Approval |
| Typical device class | Class I and Class II (lower-to-moderate risk) | Class III (highest risk) |
| Evidence required | Demonstration that the device is substantially equivalent to a legally marketed predicate device | Independent clinical trials demonstrating safety and effectiveness |
| Timeline | Generally several months to a year | Generally years |
| Examples in this category | EEG amplifiers, biofeedback systems, cranial electrotherapy stimulators (CES) for insomnia | Implantable pacemakers, deep brain stimulators, certain Class III cardiac and neurostimulation implants |
Outside the explicit FDA-cleared indications, all clinical and research observations are framed in terms of practitioner experience, clinical observation, and research investigation rather than RCT-level efficacy claims.
“Research use only” means the product is designated for academic and investigational use and is not intended to diagnose, treat, cure, or prevent any disease. Capabilities such as the Neurofeedback module, the Stimulation Targeting Tool, the Statistical Comparison Tool, the AI Profiler and Protocol Generator, and NF64 are research-use-only. They are intended for educational and research purposes and are not professional medical advice, diagnosis, or treatment.
Yes. EEG, QEEG, ERP, and neurostimulation are technical disciplines, and NeuroField equipment is built for trained practitioners. Most users come to NeuroField with prior background in clinical psychology, neuropsychology, neurology, biofeedback, or applied neuroscience, and add NeuroField-specific training on top of that foundation.
Most professional users hold one or more of the following: BCN (Board Certification in Neurofeedback), QEEG-T (QEEG Technician), QEEG-D (QEEG Diplomat), and a clinical license such as Psychologist, LMFT, LCSW, MD, DO, RN, OT, SLP, or other state-recognized health professional license. The BCN is administered by the Biofeedback Certification International Alliance (BCIA), and the QEEG-T and QEEG-D are administered by the IQCB (International QEEG Certification Board).
Yes. Select training is available for NeuroField practitioners. Select information on available programs is provided through the client portal once a purchase has been completed.
The Q21 outputs clean, high-resolution EEG data that integrates with the NeuroField Analysis Suite and is broadly compatible with industry-standard EEG analysis pipelines, including EEGLAB. The Suite generates structured Microsoft Word reports for documentation and supports import/export workflows that fit typical clinical and research environments. For specific compatibility questions with another platform, contact NeuroField technical support.
Purchases are made through NeuroField.com directly. Our Buy Now Store is fully automated and integrated, allowing for instant purchase approvals for hardware and immediate access for software and AI purchases. All sales must be made within the United States of America. Sales can be reached at 760-872-4200, Monday–Friday, 8 a.m.–5 p.m. PT.
Address:
NeuroField
1836 State Street
Santa Barbara, CA 93101.
Inquiries received after business hours are answered on the next business day.
Yes. NeuroField has a dedicated research tier including NF64, the AI Profiler and Protocol Generator, the Stimulation Targeting Tool, and the Statistical Comparison Tool. Institutional and grant-funded purchases are supported, and research-only designations are clearly stated on every relevant product.
Yes. Genesis is FDA-cleared for the treatment of chronic insomnia, and home use requires a qualifying insomnia diagnosis and prescription. The diagnosis may be provided by your physician, established through the Insomnia Severity Index (ISI) assessment, or evaluated by NeuroField’s in-house physician via our in-house evaluation form. Begin the process by going to our store on neurofield.com, selecting the product, and following the instructions to either submit your existing diagnosis and prescription, or complete the NeuroField Insomnia Evaluation Form to be evaluated by our clinical doctors if qualifying criteria are met.
Technical support is available Monday–Friday, 8 a.m.–5 p.m. Pacific Time.
Email contact@neurofield.com or call/text 760-920-4792. Inquiries received after business hours are answered on the next business day. Additionally, NeuroField customers are given access to our Client Portal, which includes forum-based, community-contributed support.
Most in-stock NeuroField hardware ships within 5–7 business days of order confirmation. Most software is available immediately upon purchase.
All hardware ships from Santa Barbara, California. Software is delivered via secure download links available in your Client Portal.
No. NeuroField ships to the United States. If you are outside of the U.S., Please contact us to discuss further at contact@neurofield.com.
Tracking numbers are emailed automatically when your order leaves our facility. If you have not received a tracking number within 7 business days of order confirmation, contact contact@neurofield.com.
Hardware returns are accepted within 30 days of delivery for unused, undamaged units in original packaging. A restocking fee may apply. Software licenses and AI Profiler credits are non-refundable once activated.
Disclaimer: The NeuroField Q21 EEG is FDA 510(k) cleared as an electroencephalography device. The NeuroField Analysis Suite is FDA 510(k) cleared for EEG and ERP acquisition and analysis. Genesis is FDA 510(k) cleared for the treatment of chronic insomnia. NeuroField64, the AI Profiler and Protocol Generator, the Neurofeedback module, the Stimulation Targeting Tool, and the Statistical Comparison Tool are designated for research use only. Research-only products are not intended to diagnose, treat, cure, or prevent any disease.
